135 related articles for article (PubMed ID: 35447031)
1. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
5. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.
Li Y; Luo X; Guo Q; Nie Y; Wang T; Zhang C; Huang Z; Wang X; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
J Med Chem; 2018 Apr; 61(7):3166-3192. PubMed ID: 29518312
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
11. FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Chen G; Sun L; Gu X; Ai L; Yang J; Zhang Z; Hou P; Wang Y; Ou X; Jiang X; Qiao X; Ma Q; Niu N; Xue J; Zhang H; Yang Y; Liu C
Sci China Life Sci; 2023 Dec; 66(12):2805-2817. PubMed ID: 37460715
[TBL] [Abstract][Full Text] [Related]
12. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 6-[(3
Czako B; Sun Y; McAfoos T; Cross JB; Leonard PG; Burke JP; Carroll CL; Feng N; Harris AL; Jiang Y; Kang Z; Kovacs JJ; Mandal P; Meyers BA; Mseeh F; Parker CA; Yu SS; Williams CC; Wu Q; Di Francesco ME; Draetta G; Heffernan T; Marszalek JR; Kohl NE; Jones P
J Med Chem; 2021 Oct; 64(20):15141-15169. PubMed ID: 34643390
[TBL] [Abstract][Full Text] [Related]
14. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
15. Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer.
Wang R; Xu K; Gao F; Huang J; Guan X
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188590. PubMed ID: 34271137
[TBL] [Abstract][Full Text] [Related]
16. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
17. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Kwon SJ; Ahn D; Yang HM; Kang HJ; Chung SJ
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562835
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
Gao G; Li J; Cao Y; Li X; Qian Y; Wang X; Li M; Qiu Y; Wu T; Wang L; Fang M
Eur J Med Chem; 2023 Dec; 261():115858. PubMed ID: 37837671
[TBL] [Abstract][Full Text] [Related]
19. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
